株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

インドネシアの医薬品市場

The Pharmaceutical Market: Indonesia

発行 Espicom Business Intelligence 商品コード 242158
出版日 ページ情報 英文 117 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
インドネシアの医薬品市場 The Pharmaceutical Market: Indonesia
出版日: 2013年01月31日 ページ情報: 英文 117 Pages
担当者のコメント
このシリーズは、他にも調査対象国がございます。詳細はお問合せください。
概要

当レポートでは、インドネシアの医薬品市場について、市場全体の動向と法規制、 医薬品流通チャネルなどを分析し、OTC医薬品、ジェネリック医薬品、 バイオ医薬品・バイオシミラーなどのセグメント別の動向、市場の機会と課題などを併せ、 概略下記の構成でお届けいたします。

目次

エグゼクティブサマリー

  • スナップショット: Espicom の戦略的分析
  • スナップショット: 主要データ予測

マクロ環境

  • 政治環境
  • 経済環境
  • 法環境
  • 人口統計

疫学

  • 病気の負荷
  • 羅漢率

ヘルスケア - 保健統計付

  • 組織・機構
  • 医療費
  • インフラストラクチャー
  • サービス
  • 労働力

規制関連情報

  • 国際機関
  • 国内当局
  • 規制の進展状況
  • 製造管理および品質管理に関する基準
  • 市場登録
  • 医薬品 標識付け
  • プロモーション

価格決定および償還

流通チャネル

  • 医薬品 卸売り
  • 医薬品 小売

市場分析

  • 規模
  • 製品開発
  • 製造
  • 貿易

競合状況

  • 事業者団体
  • 見本市
  • 企業情報

OTC 医薬品

  • 市場規模
  • 競合状況

ジェネリック医薬品

  • 規制
  • 市場規模
  • 競合状況

生物製剤/バイオシミラー

  • 規制
  • 競合状況

結び: 機会と課題

  • Espicom の戦略的分析
  • レーダー解析
  • SWOT分析

関係各機関・組織一覧

  • 政府組織
  • 製薬会社
  • 業界団体

図表


このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

Summary

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

Description

THE PHARMACEUTICAL MARKET: INDONESIA - REVIEW

Environmentally, Indonesia is particularly prone to natural disasters, as the recent earthquakes, tsunamis and volcanic eruptions have illustrated. Politically, a dominant feature of President Yudhoyono's presidency has been to curb the corruption that has so frequently plagued Indonesia. Economically, Indonesia's economy is projected to become the sixth largest in the Asia Pacific region by 2016, but if the rupiah continues to devaluate against the dollar it could affect the Indonesian pharmaceutical market in US dollar terms. Legally, Indonesia remains on the USTR's Special 301 Priority Watch List in 2011, due to the prevalence of counterfeit pharmaceuticals. Demographically, the population will be the third largest in the Asia Pacific region by 2016.

The Indonesian Pharmaceutical Manufacturers Association (GP Farmasi) announced that 20 of its members had increased the price of certain drugs by up to 10.0%, at the start of the 2011. Members of GP Farmasi have raised their drug prices in response to rising inflation, a decision by regional authorities to increase the minimum wage and an import tax imposed on raw materials for drug manufacturing. In February 2011, the Ministry of Health announced that it would review the prices of generic drugs, in light of the fact that the increase in tax on raw materials has prompted pharmaceutical companies to raise the prices of branded drugs. Many pharmaceutical companies have stated that, in their view, the prices of generic drugs are unreasonably low.

Due to the sheer size of the population, Indonesia cannot simply be dismissed. The Indonesian pharmaceutical market is projected to grow at a high single-digit CAGR in US dollar terms during the forecast period, and it will be the sixth largest pharmaceutical market in the Asia Pacific region by 2016. In 2010, there were around 250 pharmaceutical manufacturers, with the vast majority located in Java. However, despite the country possessing huge manufacturing capabilities, the complete lack of R&D in local companies could affect the market, especially if IPR regulations were tightened. Although multinationals will be unhappy at the legislation requiring all drugs in the Indonesian market to have been manufactured in Indonesia, it could potentially reduce costs in the long term for both the manufacturer and the consumer.

ENHANCED STRATEGIC INTELLIGENCE

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

Table of Contents

Executive Summary 7

SWOT Analysis 9

  • Indonesia Pharmaceutical And Healthcare Industry SWOT 9
  • Indonesia Political SWOT 10
  • Indonesia Economic SWOT 10
  • Indonesia Business Environment SWOT 11

Pharmaceutical Risk/Reward Ratings 12

  • Table: Asia Pacific Pharmaceutical And Healthcare Risk/Reward Ratings, Q113 12
  • Rewards 13
  • Risks 13

Market Summary - Indonesia 15

Regulatory Regime 16

  • Table: New Drug Approvals, 2010 17
  • Pharmaceutical Advertising 18
  • Regional Harmonisation 19
  • Intellectual Property Issues 20
  • Compulsory Licensing 22
  • Counterfeit Drugs 22
  • Generic Drug Legislation 24
  • Labelling Requirements 25
  • Free Trade Agreements 25
  • Pricing Regime 26
  • Reimbursement Regime 28

Industry Trends And Developments 30

  • Epidemiology 30
  • Non-Communicable Diseases 31
  • Communicable Diseases 33
  • Public Health Developments 35
  • Table: UN Millennium Development Goals For Indonesia 36
  • Healthcare System 37
  • Health Insurance 39
  • Healthcare System Reform 41
  • Research & Development 43
  • Clinical Trials 44
  • Herbal Medicines 45
  • Medical Devices 46

Industry Forecast Scenario 47

  • Pharmaceutical Market Forecast 47
  • Table: Pharmaceutical Sales, 2008-2016 48
  • Healthcare Market Forecast 49
  • Table: Overall Healthcare Expenditure, 2008-2016 51
  • Table: Government Healthcare Expenditure, 2008-2016 52
  • Table: Private Healthcare Expenditure, 2008-2016 52
  • Key Growth Factors - Macroeconomic 53
  • TABLE: Indonesia Long-Term Macroeconomic Forecasts 55
  • Prescription Drug Market Forecast 56
  • Table: Prescription Drug Sales, 2008-2016 57

Patented Drug Market Forecast 58

  • Table: Patented Drug Sales, 2008-2016 59
  • Generic Drug Market Forecast 60
  • Table: Generic Drug Sales, 2008-2016 62
  • OTC Medicine Market Forecast 63
  • Table: OTC Medicine Sales, 2008-2016 64
  • Table: OTC Medicine Sales, 2004-2010 65
  • Pharmaceutical Trade Forecast 66
  • Table: Pharmaceutical Trade, 2008-2016 68
  • Medical Device Market Forecast 69
  • Table: Medical Device Sales, 2008-2016 70
  • Other Healthcare Data 71
  • Key Risks To BMI's Forecast Scenario 72

Competitive Landscape 73

  • Pharmaceutical Industry 73
  • Table: Pharmaceutical Manufacturers By Region, 2000-2010 73
  • Table: Selected List Of Pharmaceutical Business Areas With Restricted Conditions 74
  • Table: Top-10 Pharmaceutical Companies According To Market Capitalisation 75
  • Domestic Industry 75
  • Foreign Industry 77
  • Table: Members Of The International Pharmaceutical Manufacturers Group (IPMG) 77
  • Recent Pharmaceutical Sector Developments 78
  • Pharmaceutical Wholesaling 78
  • Table: Pharmaceutical Wholesalers By Region, 2000-2010 79
  • Pharmaceutical Retail 80
  • Table: Pharmacies By Region, 2000-2010 80
  • Table: Drug Stores By Region, 2001-2010 81

Company Profiles 83

  • Domestic Companies 83
  • Soho Group 83
  • Darya-Varia Group 84
  • PT Kalbe Farma 86
  • PT Bio Farma 89
  • Kimia Farma 91
  • Combiphar PT 94
  • Multinational Companies 96
  • Sanofi 96
  • Pfizer 98
  • Novartis 100
  • GlaxoSmithKline 102
  • Merck & Co 104
  • Bayer 106
  • Merck Group 107

Demographic Outlook 109

  • Table: Population By Age Group, 1990-2020 ('000) 110
  • Table: Population By Age Group, 1990-2020 (% of total) 111
  • Table: Key Population Ratios, 1990-2020 112
  • Table: Rural/Urban Population Split, 1990-2020 112

BMI Methodology 113

  • How We Generate Our Pharmaceutical Industry Forecasts 113
  • Pharmaceutical Risk/Reward Ratings Methodology 114
  • Ratings Overview 114
  • Table: Pharmaceutical Business Environment Indicators 115
  • Weighting 116
  • Table: Weighting Of Components 116
  • Sources 116
Back to Top